Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01045_DB04938_nanopub.RArU084YA0ji51dGMOJ-6L-foDR6kqZ8h8kJ6SI1Elnps#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01045_DB04938 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01045_DB04938 label "DDI between Rifampicin and Ospemifene - Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect. [drugbank_resource:DB01045_DB04938]" assertion.
- drugbank_resource:DB01045_DB04938 identifier "drugbank_resource:DB01045_DB04938" assertion.
- drugbank_resource:DB01045_DB04938 title "DDI between Rifampicin and Ospemifene - Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect." assertion.
- drugbank:DB01045 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01045_DB04938 assertion.
- drugbank:DB04938 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01045_DB04938 assertion.